Update on the Role of Rifaximin in Digestive Diseases

J 2023

Update on the Role of Rifaximin in Digestive Diseases

DUMITRASCU, Dan, Igor BAKULIN, Annalisa BERZIGOTTI, Marilia CRAVO, Laura GOMBOSOVA et. al.

Basic information

Original name

Update on the Role of Rifaximin in Digestive Diseases

Authors

DUMITRASCU, Dan (guarantor), Igor BAKULIN, Annalisa BERZIGOTTI, Marilia CRAVO, Laura GOMBOSOVA, Milan LUKAS, Anna PIETRZAK, Jose Maria REMES-TROCHE, Manuel ROMERO-GOMEZ, Mercedes Amieva BALMORI, Tiago Curdia GONCALVES, Lamine HAMZAOUI, Radovan JURICEK, Leticia MOREIRA, Katarzyna NEUBAUER, Teodora SURDEA-BLAGA, Igor N TIKHONOV, Jan TRNA (203 Czech Republic, belonging to the institution), Gianluca IANIRO, Francesca Romana PONZIANI and Antonio GASBARRINI

Edition

Journal of Gastrointestinal and Liver Diseases, CLUJ-NAPOCA, MEDICAL UNIV PRESS, 2023, 1841-8724

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30219 Gastroenterology and hepatology

Country of publisher

Romania

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.100 in 2022

RIV identification code

RIV/00216224:14110/23:00131030

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.15403/jgld-4871

UT WoS

000972987600016

Keywords in English

liver cirrhosis; hepatic encephalopathy; irritable bowel syndrome; diverticular disease; gut microbiome; rifaximin-?; symptomatic uncomplicated diverticular disease

Abstract

V originále

Various environmental factors affecting the human microbiota may lead to gut microbial imbalance and to the development of pathologies. Alterations of gut microbiota have been firmly implicated in digestive diseases such as hepatic encephalopathy, irritable bowel syndrome and diverticular disease. However, while these three conditions may all be related to dysfunction of the gut-liver-brain axis, the precise pathophysiology appears to differ somewhat for each. Herein, current knowledge on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease are reviewed, with a special focus on the gut microbiota modulation associated with these disorders during therapy with rifaximin. In general, the evidence for the efficacy of rifaximin in hepatic encephalopathy appears to be well consolidated, although it is less supported for irritable bowel syndrome and diverticular disease. We reviewed current clinical practice for the management of these clinical conditions and underlined the desirability of more real-world studies to fully understand the potential of rifaximin in these clinical situations and obtain even more precise indications for the use of the drug.

Citovat

DUMITRASCU, Dan, Igor BAKULIN, Annalisa BERZIGOTTI, Marilia CRAVO, Laura GOMBOSOVA, Milan LUKAS, Anna PIETRZAK, Jose Maria REMES-TROCHE, Manuel ROMERO-GOMEZ, Mercedes Amieva BALMORI, Tiago Curdia GONCALVES, Lamine HAMZAOUI, Radovan JURICEK, Leticia MOREIRA, Katarzyna NEUBAUER, Teodora SURDEA-BLAGA, Igor N TIKHONOV, Jan TRNA, Gianluca IANIRO, Francesca Romana PONZIANI and Antonio GASBARRINI. Update on the Role of Rifaximin in Digestive Diseases. Journal of Gastrointestinal and Liver Diseases. CLUJ-NAPOCA: MEDICAL UNIV PRESS, 2023, vol. 32, No 1, p. 92-109. ISSN 1841-8724. Available from: https://dx.doi.org/10.15403/jgld-4871.

@article{2293054,
   author = {Dumitrascu, Dan and Bakulin, Igor and Berzigotti, Annalisa and Cravo, Marilia and Gombosova, Laura and Lukas, Milan and Pietrzak, Anna and RemesandTroche, Jose Maria and RomeroandGomez, Manuel and Balmori, Mercedes Amieva and Goncalves, Tiago Curdia and Hamzaoui, Lamine and Juricek, Radovan and Moreira, Leticia and Neubauer, Katarzyna and SurdeaandBlaga, Teodora and Tikhonov, Igor N and Trna, Jan and Ianiro, Gianluca and Ponziani, Francesca Romana and Gasbarrini, Antonio},
   article_location = {CLUJ-NAPOCA},
   article_number = {1},
   doi = {http://dx.doi.org/10.15403/jgld-4871},
   keywords = {liver cirrhosis; hepatic encephalopathy; irritable bowel syndrome; diverticular disease; gut microbiome; rifaximin-?; symptomatic uncomplicated diverticular disease},
   language = {eng},
   issn = {1841-8724},
   journal = {Journal of Gastrointestinal and Liver Diseases},
   title = {Update on the Role of Rifaximin in Digestive Diseases},
   url = {https://jgld.ro/jgld/index.php/jgld/article/view/4871},
   volume = {32},
   year = {2023}
}

TY  - JOUR
ID  - 2293054
AU  - Dumitrascu, Dan - Bakulin, Igor - Berzigotti, Annalisa - Cravo, Marilia - Gombosova, Laura - Lukas, Milan - Pietrzak, Anna - Remes-Troche, Jose Maria - Romero-Gomez, Manuel - Balmori, Mercedes Amieva - Goncalves, Tiago Curdia - Hamzaoui, Lamine - Juricek, Radovan - Moreira, Leticia - Neubauer, Katarzyna - Surdea-Blaga, Teodora - Tikhonov, Igor N - Trna, Jan - Ianiro, Gianluca - Ponziani, Francesca Romana - Gasbarrini, Antonio
PY  - 2023
TI  - Update on the Role of Rifaximin in Digestive Diseases
JF  - Journal of Gastrointestinal and Liver Diseases
VL  - 32
IS  - 1
SP  - 92-109
EP  - 92-109
PB  - MEDICAL UNIV PRESS
SN  - 18418724
KW  - liver cirrhosis
KW  - hepatic encephalopathy
KW  - irritable bowel syndrome
KW  - diverticular disease
KW  - gut
KW  - microbiome
KW  - rifaximin-?
KW  - symptomatic uncomplicated diverticular disease
UR  - https://jgld.ro/jgld/index.php/jgld/article/view/4871
N2  - Various environmental factors affecting the human microbiota may lead to gut microbial imbalance and to the development of pathologies. Alterations of gut microbiota have been firmly implicated in digestive diseases such as hepatic encephalopathy, irritable bowel syndrome and diverticular disease. However, while these three conditions may all be related to dysfunction of the gut-liver-brain axis, the precise pathophysiology appears to differ somewhat for each. Herein, current knowledge on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease are reviewed, with a special focus on the gut microbiota modulation associated with these disorders during therapy with rifaximin. In general, the evidence for the efficacy of rifaximin in hepatic encephalopathy appears to be well consolidated, although it is less supported for irritable bowel syndrome and diverticular disease. We reviewed current clinical practice for the management of these clinical conditions and underlined the desirability of more real-world studies to fully understand the potential of rifaximin in these clinical situations and obtain even more precise indications for the use of the drug.
ER  -

DUMITRASCU, Dan, Igor BAKULIN, Annalisa BERZIGOTTI, Marilia CRAVO, Laura GOMBOSOVA, Milan LUKAS, Anna PIETRZAK, Jose Maria REMES-TROCHE, Manuel ROMERO-GOMEZ, Mercedes Amieva BALMORI, Tiago Curdia GONCALVES, Lamine HAMZAOUI, Radovan JURICEK, Leticia MOREIRA, Katarzyna NEUBAUER, Teodora SURDEA-BLAGA, Igor N TIKHONOV, Jan TRNA, Gianluca IANIRO, Francesca Romana PONZIANI and Antonio GASBARRINI. Update on the Role of Rifaximin in Digestive Diseases. \textit{Journal of Gastrointestinal and Liver Diseases}. CLUJ-NAPOCA: MEDICAL UNIV PRESS, 2023, vol.~32, No~1, p.~92-109. ISSN~1841-8724. Available from: https://dx.doi.org/10.15403/jgld-4871.

Detailed Information on Publication Record